Frazier Life Sciences Management, L.P. Alkermes Plc. Transaction History
Frazier Life Sciences Management, L.P.
- $2.36 Billion
- Q3 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Alkermes Plc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 700,647 shares of ALKS stock, worth $20.3 Million. This represents 0.89% of its overall portfolio holdings.
Number of Shares
700,647
Previous 1,000,647
29.98%
Holding current value
$20.3 Million
Previous $28.6 Million
26.58%
% of portfolio
0.89%
Previous 1.51%
Shares
4 transactions
Others Institutions Holding ALKS
# of Institutions
401Shares Held
176MCall Options Held
901KPut Options Held
400K-
Black Rock Inc. New York, NY29.1MShares$845 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$528 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.2MShares$297 Million0.03% of portfolio
-
State Street Corp Boston, MA8.54MShares$248 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY8.09MShares$235 Million1.98% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.77B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...